Shuyi Han

Shuyi Han

Auto-generated profile, based on publicly available information

Shuyi Han

Department of Laboratory

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
MYMingjie Yuan
Mingjie Yuan
SHShuyi Han
Shuyi Han
YJYanfei Jia
Yanfei Jia
JFJiankai Feng
Jiankai Feng
DLDuanrui Liu
Duanrui Liu
XLXiangdong Liu
Xiangdong Liu
Statins are associated with gastric cancer (GC) risk. The present study aimed to clarify the efficacy of statins on the overall survival (OS) benefits in patients with GC. Publications were retrieved from PubMed, Embase, and the Cochrane Library as of April 2022. Data from the eligible cohort, case‐control studies, and randomized control trials (RCTs) were extracted for the meta‐analysis. Hazard ratio (HR) and 95% confidence intervals (CI) were used to assess the association between statins users and OS in GC patients. Subgroup analysis was performed based on the study design (prospective vs. retrospective). A total of 6 studies encompassing 5693 GC patients were included. Statins added to the standard treatment prolonged the patient’s OS outcome (HR (95% CI): 0.72 (0.53–0.97), p = 0.032; I2 = 88.0%, pheterogeneity < 0.001). A prospective study did not find any statistically significant difference in OS between statins users vs. nonstatin users (HR (95% CI): 0.92 (0.68–1.26), p = 0.614; I2 = 11.7%, pheterogeneity = 0.322), whereas the retrospective studies showed prolonged OS in statins users (HR (95% CI): 0.63 (0.42–0.961), p = 0.032; I2 = 94.6%, pheterogeneity < 0.001). Statin users had significantly improved OS compared to nonstatin users in GC treatment. This long‐term survival benefit was only observed in the pooled analysis of retrospective studies but not in prospective studies.